Astra Zeneca Acquires Ardea Biosciences

Ardea Biosciences

Represented Ardea Biosciences in its acquisition by Astra Zeneca in a cash merger valued at $1.3 billion.*

Ardea Biosciences is an a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Astra Zeneca is a company that sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience.